Jin QY, Du SB, Yuan XJ. Exploring the prognosis of neuroblastoma in adolescents and adults: a case series and literature review. Neoplasma. 2022;69(2):464–73.

Article  PubMed  Google Scholar 

Spasov N, Spasova M. Early use of dinutuximab beta in patients with high-risk neuroblastoma. Case Rep Pediatr. 2021;2021:6610955.

PubMed  PubMed Central  Google Scholar 

Cabral J, Fernandez EI, Toy B, Secola R. Multidisciplinary clinical care in the management of patients receiving anti-GD2 immunotherapy for high-risk neuroblastoma. Paediatr Drugs. 2023;25(1):13–25.

Article  PubMed  Google Scholar 

Mastrangelo S, Rivetti S, Triarico S, Romano A, Attinà G, Maurizi P, et al. Mechanisms, characteristics, and treatment of neuropathic pain and peripheral neuropathy associated with dinutuximab in neuroblastoma patients. Int J Mol Sci. 2021;22(23):12648.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed AA, Zhang L, Reddivalla N, Hetherington M. Neuroblastoma in children: update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol. 2017;34(3):165–85.

Article  PubMed  Google Scholar 

Chan GC, Chan CM. Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma. Biomolecules. 2022;12(3):358.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furman WL. Monoclonal antibody therapies for high risk neuroblastoma. Biologics. 2021;15:205–19.

PubMed  PubMed Central  Google Scholar 

Larrosa C, Mora J, Cheung NK. Global impact of monoclonal antibodies (mAbs) in children: a focus on anti-GD2. Cancers. 2023;15(14):3729.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dalianis T, Lukoseviciute M, Holzhauser S, Kostopoulou ON. New approaches towards targeted therapy for childhood neuroblastoma. Anticancer Res. 2023;43(9):3829–39.

Article  CAS  PubMed  Google Scholar 

Cheung IY, Cheung NV, Modak S, Mauguen A, Feng Y, Basu E, et al. Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease rogression. J Clin Oncol. 2021;39(3):215–26.

Article  CAS  PubMed  Google Scholar 

Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, et al. Long-term follow-up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021;27(8):2179–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30(26):3264–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flaadt T, Ebinger M, Schreiber M, Ladenstein RL, Simon T, Lode HN, et al. Multimodal therapy with consolidating haploidentical stem cell transplantation and dinutuximab beta for patients with high-risk neuroblastoma and central nervous system relapse. J Clin Med. 2023;12(19):6196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perez Horta Z, Goldberg JL, Sondel PM. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy. 2016;8(9):1097–117.

Article  PubMed  PubMed Central  Google Scholar 

Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1617–29.

Article  CAS  PubMed  Google Scholar 

Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK. Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-nacrophage colony-stimulating factor in patients with resistant neuroblastoma:a phase 1 clinical trial. JAMA Oncol. 2018;4(12):1729–35.

Article  PubMed  PubMed Central  Google Scholar 

Achbergerová M, Hederová S, Mikesková M, Husáková K, Hrašková A, Kolenová A. Implementation of immunotherapy into the treatment of neuroblastoma-single center experience with the administration of dinutuximab and management of its adverse effects. Klin Onkol. 2020;33(5):372–8.

PubMed  Google Scholar 

Muñoz JP, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, et al. Early salvage chemo-immunotherapy with irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) for patients with primary refractory high-risk neuroblastoma provide the best chance for long-term outcomes. Cancers. 2023;15(19):4837.

Article  PubMed  PubMed Central  Google Scholar 

Varo A, Castañeda A, Chamorro S, Muñoz JP, Gorostegui M, Celma MS, et al. Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab. Front Oncol. 2023;13:1164949.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kushner BH, Modak S, Kramer K, Basu EM, Iglesias-Cardenas F, Roberts SS, et al. Immunotherapy with anti-G(D2) monoclonal antibody in infants with high-risk neuroblastoma. Int J Cancer. 2023;152(2):259–66.

Article  CAS  PubMed  Google Scholar 

Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796–803.

Article  PubMed  PubMed Central  Google Scholar 

Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020;10:1000.

Article  PubMed  PubMed Central  Google Scholar 

Markham A. Naxitamab: first approval. Drugs. 2021;81(2):291–6.

Article  CAS  PubMed  Google Scholar 

Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN phase 1 study. MAbs. 2013;5(5):801–9.

Article  PubMed  PubMed Central  Google Scholar 

Chen JJ, Huo XC, Wang SX, Wang F, Zhao Q. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration Adverse Event Reporting System. Int J Clin Pharm. 2022;44(6):1351–60.

Article  CAS  PubMed  Google Scholar 

van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10.

Article  PubMed  Google Scholar 

Shao QH, Yin XD, Zeng N, Zhou ZX, Mao XY, Zhu Y, et al. Stevens-Johnson syndrome following non-steroidal anti-inflammatory drugs: a real-world analysis of post-marketing surveillance data. Front Pediatr. 2022;10: 896867.

Article  PubMed  PubMed Central  Google Scholar 

Yang H, Yu X, An Z. Cutaneous toxicity associated with enfortumab vedotin: a real-world study leveraging U.S. Food and Drug Administration Adverse Event Reporting System. Front Oncol. 2021;11:801199.

Article  CAS  PubMed  Google Scholar 

Guan Y, Ji L, Zheng L, Yang J, Qin Y, Ding N, et al. Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions. Front Pharmacol. 2022;13: 892503.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Voeller J, Sondel PM. Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma. J Pediatr Hematol Oncol. 2019;41(3):163–9.

Article  PubMed  PubMed Central  Google Scholar 

Dhillon S. Dinutuximab: first global approval. Drugs. 2015;75(8):923–7.

Article  CAS  PubMed  Google Scholar 

Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol. 2005;42(11):1311–9.

Article  CAS  PubMed  Google Scholar 

Machy P, Mortier E, Birklé S. Biology of GD2 ganglioside: implications for cancer immunotherapy. Front Pharmacol. 2023;14:1249929.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung C, Boterberg T, Lucas J, Panoff J, Valteau-Couanet D, Hero B, et al. Neuroblastoma. Pediatr Blood Cancer. 2021;68 Suppl. 2(Suppl. 2):e28473.

Kumar H, Gupta R. Anti-disialoganglioside-2 monoclonal antibodies as an emerging therapeutic approach in treatment of high-risk neuroblastoma. Curr Pharmacol Rep. 2022;8(2):112–20.

Article  Google Scholar 

Mueller I, Ehlert K, Endr